Effect of body mass index on treatment response of biologic/targeted-synthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. A systematic review
Tài liệu tham khảo
Robinson, 2021, Axial spondyloarthritis: concept, construct, classification and implications for therapy, Nat Rev Rheumatol, 17, 109, 10.1038/s41584-020-00552-4
Sharip, 2020, 10, 10
Smolen, 2020, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update, Ann Rheum Dis, 79, 685, 10.1136/annrheumdis-2019-216655
Gossec, 2020, EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update, Ann Rheum Dis, 79, 700, 10.1136/annrheumdis-2020-217159
Ramiro, 2023, ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update, Ann Rheum Dis, 82, 19, 10.1136/ard-2022-223296
Gialouri, 2022, Choosing the appropriate target for the treatment of psoriatic arthritis: TNFα, IL-17, IL-23 or JAK inhibitors?, Mediterr J Rheumatol, 33, 150, 10.31138/mjr.33.1.150
Hsiao, 2019, Patient preferences for rheumatoid arthritis treatment, Curr Opin Rheumatol, 31, 256, 10.1097/BOR.0000000000000591
van Onna, 2022, Challenges in the management of older patients with inflammatory rheumatic diseases, Nat Rev Rheumatol, 18, 326, 10.1038/s41584-022-00768-6
Ferguson, 2019, Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions, Nat Rev Rheumatol, 15, 461, 10.1038/s41584-019-0256-0
Bhole, 2012, Differences in body mass index among individuals with PsA, psoriasis, RA and the general population, Rheumatology (Oxford), 51, 552, 10.1093/rheumatology/ker349
Liew, 2020, Association of body mass index on disease activity in axial spondyloarthritis: systematic review and meta-analysis, RMD Open, 6, 10.1136/rmdopen-2020-001225
Lupoli, 2016, Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: a systematic review and meta-analysis, Arthritis Res Ther, 18, 297, 10.1186/s13075-016-1194-8
Liu, 2017, Impact of obesity on remission and disease activity in rheumatoid arthritis: a systematic review and Meta-analysis, Arthritis Care Res, 69, 157, 10.1002/acr.22932
Singh, 2018, Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis, PLoS One, 13, 10.1371/journal.pone.0195123
Zurita Prada, 2021, Influence of smoking and obesity on treatment response in patients with axial spondyloarthritis: a systematic literature review, Clin Rheumatol, 40, 1673, 10.1007/s10067-020-05319-6
Higgins, 2022, Chapter 8: Assessing risk of bias in a randomized trial. Cochrane Handbook for Systematic Reviews of Interventions version 6.3, Cochrane
Zeng, 2015, The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review, J Evid Based Med, 8, 2, 10.1111/jebm.12141
Wells
Abhishek, 2010, Anti-TNF-alpha agents are less effective for the treatment of rheumatoid arthritis in current smokers, J Clin Rheumatol: Pract Rep Rheum Musculoskel Dis, 16, 15, 10.1097/RHU.0b013e3181ca4a2a
Bergstra, 2020, Body mass index and treatment survival in patients with RA starting treatment with TNFα-inhibitors: long-term follow-up in the real-life METEOR registry, RMD Open, 6, 10.1136/rmdopen-2020-001203
Gremese, 2013, Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine, Arthritis Care Res, 65, 94, 10.1002/acr.21768
Klaasen, 2011, Body mass index and clinical response to infliximab in rheumatoid arthritis, Arthritis Rheum, 63, 359, 10.1002/art.30136
Hamann, 2019, Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-treated rheumatoid arthritis patients, Rheumatology (Oxford), 58, 2162, 10.1093/rheumatology/kez188
Ogdie, 2019, Predictors of achieving remission among patients with psoriatic arthritis initiating a tumor necrosis factor inhibitor, J Rheumatol, 46, 475, 10.3899/jrheum.171034
Schäfer, 2020, Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis, Rheumatology (Oxford), 59, 1916, 10.1093/rheumatology/kez535
Heimans, 2013, Association of high body mass index with decreased treatment response to combination therapy in recent-onset rheumatoid arthritis patients, Arthritis Care Res, 65, 1235, 10.1002/acr.21978
Kaeley, 2018, Clinical responses and synovial vascularity in obese rheumatoid arthritis patients treated with adalimumab and methotrexate, J Rheumatol, 45, 1628, 10.3899/jrheum.171232
Levitsky, 2017, Obesity is a strong predictor of worse clinical outcomes and treatment responses in early rheumatoid arthritis: results from the SWEFOT trial, RMD Open, 3, 10.1136/rmdopen-2017-000458
Iannone, 2013, Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy, Scand J Rheumatol, 42, 41, 10.3109/03009742.2012.715186
di Minno, 2013, Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis, Arthritis Care Res, 65, 141, 10.1002/acr.21711
Mease, 2015, Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry, RMD Open, 1, 10.1136/rmdopen-2015-000181
Chiricozzi, 2017, Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-Centre, retrospective study, J Eur Acad Dermatol Venereol: JEADV, 31, 304, 10.1111/jdv.13771
Højgaard, 2016, The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries, Rheumatology (Oxford), 55, 2191, 10.1093/rheumatology/kew326
Vieira-Sousa, 2020, Real-world Longterm effectiveness of tumor necrosis factor inhibitors in psoriatic arthritis patients from the rheumatic diseases Portuguese register, J Rheumatol, 47, 690, 10.3899/jrheum.181272
Eviatar, 2022, Secukinumab real world drug retention compared to TNF-alpha inhibitors in psoriatic arthritis, Clin Exp Rheumatol, 40, 15, 10.55563/clinexprheumatol/1sx5yk
Mease, 2022, Potential impact of sex and body mass index on response to therapy in psoriatic arthritis: post-hoc analysis of results from the SEAM-PsA trial, J Rheumatol, 49, 885, 10.3899/jrheum.211037
Gremese, 2014, Body weight, gender and response to TNF-α blockers in axial spondyloarthritis, Rheumatology (Oxford), 53, 875, 10.1093/rheumatology/ket433
van Weely, 2016, Continuous improvement of physical functioning in ankylosing spondylitis patients by tumor necrosis factor inhibitors: three-year Followup and predictors, Arthritis Care Res, 68, 1522, 10.1002/acr.22869
Jeong, 2018, Drug survival of tumor necrosis factor α inhibitors in patients with ankylosing spondylitis in Korea, Korean J Intern Med, 33, 407, 10.3904/kjim.2016.042
Almirall, 2017, Treatment with ustekinumab in a Spanish cohort of patients with psoriasis and psoriatic arthritis in daily clinical practice, Clin Rheumatol, 36, 439, 10.1007/s10067-016-3464-x
Smolen, 2021, Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results, Ann Rheum Dis, 80, 1419, 10.1136/annrheumdis-2021-220263
Ritchlin, 2022, Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies, RMD Open, 8, 10.1136/rmdopen-2022-002195
Pantano, 2022, Secukinumab efficacy in patients with PsA is not dependent on patients’ body mass index, Ann Rheum Dis, 81, 10.1136/annrheumdis-2020-217251
Alonso, 2021, Multicenter study of Secukinumab survival and safety in Spondyloarthritis and psoriatic arthritis: SEcukinumab in Cantabria and ASTURias study, Front Med, 8, 10.3389/fmed.2021.679009
Ritchlin, 2014, Ann Rheum Dis, 73, 990, 10.1136/annrheumdis-2013-204655
Armağan, 2023, Drug retention rate and predictive factors of drug survival for secukinumab in radiographic axial spondyloarthritis, Rheumatol Int, 43, 147, 10.1007/s00296-022-05213-1
Abuhelwa, 2020, Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs, Sci Rep, 10, 18634, 10.1038/s41598-020-75673-7
Ahn, 2022, Predictive factors for rheumatoid arthritis flare after switching from intravenous to subcutaneous formulation of tocilizumab in real-world practice, J Korean Med Sci, 37, 10.3346/jkms.2022.37.e138
Arad, 2019, Association of Serum Tocilizumab Trough Concentrations with clinical disease activity index scores in adult patients with rheumatoid arthritis, J Rheumatol, 46, 1577, 10.3899/jrheum.181431
Gardette, 2016, Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study, Clin Rheumatol, 35, 857, 10.1007/s10067-016-3183-3
Huang, 2019, Body mass index and clinical response to tocilizumab in patients with rheumatoid arthritis, Archiv Rheumatol, 34, 406, 10.5606/ArchRheumatol.2019.7146
Iwamoto, 2016, Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis, Mod Rheumatol, 26, 662, 10.3109/14397595.2015.1129692
Koike, 2014, Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan, J Rheumatol, 41, 15, 10.3899/jrheum.130466
Nagy, 2022, Real-world evidence on methotrexate-free subcutaneous tocilizumab therapy in patients with rheumatoid arthritis: 24-week data from the SIMPACT study, Rheumatol Adv Pract, 6, rkac038, 10.1093/rap/rkac038
Pappas, 2020, Effectiveness of tocilizumab in patients with rheumatoid arthritis is unaffected by comorbidity Burden or obesity: data from a US registry, J Rheumatol, 47, 1464, 10.3899/jrheum.190282
Pers, 2015, Response to tocilizumab in rheumatoid arthritis is not influenced by the body mass index of the patient, J Rheumatol, 42, 580, 10.3899/jrheum.140673
Ogata, 2015, Sustainable efficacy of switching from intravenous to subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis, Arthritis Care Res, 67, 1354, 10.1002/acr.22598
Ogata, 2014, Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis, Arthritis Care Res, 66, 344, 10.1002/acr.22110
Ogata, 2019, Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: results from the open-label extension of the SHINOBI study, Mod Rheumatol, 29, 767, 10.1080/14397595.2018.1533514
Alten, 2017, Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study, RMD Open, 3, 10.1136/rmdopen-2017-000538
Di Carlo, 2019, Body mass index as a driver of selection of biologic therapy in rheumatoid arthritis. Results from the US-CLARA study, Eur J Intern Med, 66, 57, 10.1016/j.ejim.2019.05.017
Gardette, 2016, Body mass index and response to abatacept in rheumatoid arthritis, Eur J Clin Investig, 46, 1048, 10.1111/eci.12691
Li, 2019, Population pharmacokinetics and exposure-response relationship of intravenous and subcutaneous Abatacept in patients with rheumatoid arthritis, J Clin Pharmacol, 59, 245, 10.1002/jcph.1308
McInnes, 2019, Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial, RMD Open, 5, 10.1136/rmdopen-2019-000934
Ottaviani, 2015, Body mass index and response to rituximab in rheumatoid arthritis, Joint Bone Spine, 82, 432, 10.1016/j.jbspin.2015.02.011
Spinelli, 2021, Effectiveness and safety of baricitinib in rheumatoid arthritis: a monocentric, longitudinal, real-life experience, Clin Exp Rheumatol, 39, 525, 10.55563/clinexprheumatol/lfg83z
Dikranian, 2022, Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies, RMD Open, 8, 10.1136/rmdopen-2021-002103
Genovese, 2018, Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis, Rheumatology (Oxford), 57, 900, 10.1093/rheumatology/kex489
Giles, 2021, Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis, RMD Open, 7, 10.1136/rmdopen-2020-001486
Fragoulis, 2020, Higher depression rates and similar cardiovascular comorbidity in psoriatic arthritis compared with rheumatoid arthritis and diabetes mellitus, Ther Adv Musculoskelet Dis, 12, 10.1177/1759720X20976975
Kearsley-Fleet, 2018, Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology biologics register for rheumatoid arthritis, Ann Rheum Dis, 77, 1405, 10.1136/annrheumdis-2018-213378
Haddad, 2021, Treatment persistence of biologics among patients with psoriatic arthritis, Arthritis Res Ther, 23, 44, 10.1186/s13075-021-02417-x
Ferguson, 2022, Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease-results of the immune metabolic associations in psoriatic arthritis study, Rheumatology (Oxford), 61, 1026, 10.1093/rheumatology/keab474
Nikiphorou, 2018, Inflammation, obesity and rheumatic disease: common mechanistic links. A narrative review, Therap Adv Musculoskel Dis, 10, 157, 10.1177/1759720X18783894
Ahmed, 2010, IL-17 in obesity and adipogenesis, Cytokine Growth Factor Rev, 21, 449, 10.1016/j.cytogfr.2010.10.005
Vallejo-Yagüe, 2022, Minimal disease activity and remission in patients with psoriatic arthritis with elevated body mass index: an observational cohort study in the Swiss clinical quality management cohort, BMJ Open, 12, 10.1136/bmjopen-2022-061474
Fragoulis, 2022, Systematic literature review informing the 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases, RMD Open, 8, 10.1136/rmdopen-2022-002726